Dual Suppression of the Cyclin-dependent Kinase Inhibitors CDKN2C and CDKN1A in Human Melanoma

Overview

Journal J Natl Cancer Inst

Publisher Oxford University Press

Specialty Oncology

Date 2012 Sep 22

PMID 22997239

Citations 22

Authors

Ahmad Jalili

Christine Wagner

Mikhail Pashenkov

Gaurav Pathria

Kirsten D Mertz

Hans R Widlund

Mathieu Lupien

Jean-Philippe Brunet

Todd R Golub

Georg Stingl

David E Fisher

Sridhar Ramaswamy

Stephan N Wagner

Affiliations

Soon will be listed here.

Abstract

Resistance to BRAF(V600E) inhibitors is associated with reactivation of mitogen-activated protein kinase (MAPK) signaling at different levels in melanoma. To identify downstream effectors of MAPK signaling that could be used as potential additional therapeutic targets for BRAF(V600E) inhibitors, we used hTERT/CDK4R24C/p53DD-immortalized primary human melanocytes genetically modified to ectopically express BRAF ( V600E ) or NRAS ( G12D ) and observed induction of the AP-1 transcription factor family member c-Jun. Using a dominant negative approach, in vitro cell proliferation assays, western blots, and flow cytometry showed that MAPK signaling via BRAF(V600E) promotes melanoma cell proliferation at G1 through AP-1-mediated negative regulation of the INK4 family member, cyclin-dependent kinase inhibitor 2C (CDKN2C), and the CIP/KIP family member, cyclin-dependent kinase inhibitor 1A (CDKN1A). These effects were antagonized by pharmacological inhibition of CDKN2C and CDKN1A targets CDK2 and CDK4 in vitro. In contrast to BRAF ( V600E ) or NRAS ( G12D )-expressing melanocytes, melanoma cells have an inherent resistance to suppression of AP-1 activity by BRAF(V600E)- or MEK-inhibitors. Here, CDK2/4 inhibition statistically significantly augmented the effects of BRAF(V600E)- or MEK-inhibitors on melanoma cell viability in vitro and growth in athymic nude Foxn1 ( nu ) mice (P = .03 when mean tumor volume at day 13 was compared for BRAF(V600E) inhibitor vs BRAF(V600E) inhibitor plus CDK2/4 inhibition; P = .02 when mean tumor volume was compared for MEK inhibitor vs MEK inhibitor plus CDK2/4 inhibition; P values were calculated by a two-sided Welch t test; n = 4-8 mice per group).

Citing Articles

The anti-melanoma roles and mechanisms of tricholoma isoflavone derivative CA028.

Liang C, Jiang J, Li J, Lin X, Huang W, Lai K NPJ Sci Food. 2025; 9(1):4.

PMID: 39788977 PMC: 11718060. DOI: 10.1038/s41538-025-00370-6.

Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma.

Zacarias-Fluck M, Masso-Valles D, Giuntini F, Gonzalez-Larreategui I, Kaur J, Casacuberta-Serra S Genes Dev. 2023; 37(7-8):303-320.

PMID: 37024284 PMC: 10153459. DOI: 10.1101/gad.350078.122.

Establishment and validation of a polygene prognostic model for clear cell renal cell carcinoma.

Gan K, Zhang K, Li Y, Zhao X, Li H, Xu C Front Genet. 2022; 13:1021163.

PMID: 36338999 PMC: 9630580. DOI: 10.3389/fgene.2022.1021163.

Single-cell trajectories of melanoma cell resistance to targeted treatment.

Schmidt M, Mortensen L, Loeffler-Wirth H, Kosnopfel C, Krohn K, Binder H Cancer Biol Med. 2021; .

PMID: 34591417 PMC: 8763000. DOI: 10.20892/j.issn.2095-3941.2021.0267.

Computational Drug Repositioning Identifies Statins as Modifiers of Prognostic Genetic Expression Signatures and Metastatic Behavior in Melanoma.

Yu W, Hill S, Ricky Chan E, Pink J, Cooper K, Leachman S J Invest Dermatol. 2021; 141(7):1802-1809.

PMID: 33417917 PMC: 8238797. DOI: 10.1016/j.jid.2020.12.015.

References

Kubo A, Nakagawa K, Varma R, Conrad N, Cheng J, Lee W . The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. Clin Cancer Res. 2000; 5(12):4279-86. View

Flaherty K, Puzanov I, Kim K, Ribas A, McArthur G, Sosman J . Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363(9):809-19. PMC: 3724529. DOI: 10.1056/NEJMoa1002011. View

Dudley D, Pang L, Decker S, Bridges A, Saltiel A . A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A. 1995; 92(17):7686-9. PMC: 41210. DOI: 10.1073/pnas.92.17.7686. View

Pennati M, Campbell A, Curto M, Binda M, Cheng Y, Wang L . Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther. 2005; 4(9):1328-37. DOI: 10.1158/1535-7163.MCT-05-0022. View

Jane-Valbuena J, Widlund H, Perner S, Johnson L, Dibner A, Lin W . An oncogenic role for ETV1 in melanoma. Cancer Res. 2010; 70(5):2075-84. PMC: 2846410. DOI: 10.1158/0008-5472.CAN-09-3092. View

Hacker E, Muller H, Irwin N, Gabrielli B, Lincoln D, Pavey S . Spontaneous and UV radiation-induced multiple metastatic melanomas in Cdk4R24C/R24C/TPras mice. Cancer Res. 2006; 66(6):2946-52. DOI: 10.1158/0008-5472.CAN-05-3196. View

Halaban R, Cheng E, Zhang Y, Mandigo C, Miglarese M . Release of cell cycle constraints in mouse melanocytes by overexpressed mutant E2F1E132, but not by deletion of p16INK4A or p21WAF1/CIP1. Oncogene. 1998; 16(19):2489-501. DOI: 10.1038/sj.onc.1201773. View

Holland E, Schmid H, Kefford R, Mann G . CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas. Genes Chromosomes Cancer. 1999; 25(4):339-48. View

Ham J, Babij C, Whitfield J, Pfarr C, lAllemand D, Yaniv M . A c-Jun dominant negative mutant protects sympathetic neurons against programmed cell death. Neuron. 1995; 14(5):927-39. DOI: 10.1016/0896-6273(95)90331-3. View

10.

Lopez-Bergami P, Huang C, Goydos J, Yip D, Bar-Eli M, Herlyn M . Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell. 2007; 11(5):447-60. PMC: 1978100. DOI: 10.1016/j.ccr.2007.03.009. View

11.

Curtin J, Fridlyand J, Kageshita T, Patel H, Busam K, Kutzner H . Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005; 353(20):2135-47. DOI: 10.1056/NEJMoa050092. View

12.

Villanueva J, Vultur A, Lee J, Somasundaram R, Fukunaga-Kalabis M, Cipolla A . Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010; 18(6):683-95. PMC: 3026446. DOI: 10.1016/j.ccr.2010.11.023. View

13.

Duncia J, Santella 3rd J, Higley C, PITTS W, Wityak J, Frietze W . MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products. Bioorg Med Chem Lett. 1999; 8(20):2839-44. DOI: 10.1016/s0960-894x(98)00522-8. View

14.

Maelandsmo G, Holm R, Fodstad O, Kerbel R, Florenes V . Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions. Am J Pathol. 1996; 149(6):1813-22. PMC: 1865341. View

15.

Matsuzaki Y, Takaoka Y, Hitomi T, Nishino H, Sakai T . Activation of protein kinase C promotes human cancer cell growth through downregulation of p18(INK4c). Oncogene. 2004; 23(31):5409-14. DOI: 10.1038/sj.onc.1207702. View

16.

Sotillo R, Garcia J, Ortega S, Martin J, Dubus P, Barbacid M . Invasive melanoma in Cdk4-targeted mice. Proc Natl Acad Sci U S A. 2001; 98(23):13312-7. PMC: 60867. DOI: 10.1073/pnas.241338598. View

17.

Hennigan R, Stambrook P . Dominant negative c-jun inhibits activation of the cyclin D1 and cyclin E kinase complexes. Mol Biol Cell. 2001; 12(8):2352-63. PMC: 58599. DOI: 10.1091/mbc.12.8.2352. View

18.

Carreira S, Goodall J, Aksan I, La Rocca S, Galibert M, Denat L . Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature. 2005; 433(7027):764-9. DOI: 10.1038/nature03269. View

19.

Nazarian R, Shi H, Wang Q, Kong X, Koya R, Lee H . Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010; 468(7326):973-7. PMC: 3143360. DOI: 10.1038/nature09626. View

20.

Cuevas B, Abell A, Johnson G . Role of mitogen-activated protein kinase kinase kinases in signal integration. Oncogene. 2007; 26(22):3159-71. DOI: 10.1038/sj.onc.1210409. View